Research Paper Volume 12, Issue 11 pp 10827—10843
High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations
Figure 5. Association of MUC16 mutations with ICI therapy efficacy. (A–C) Association of MUC16 mutations with response rate to ICI therapy in male, female, and overall patients. (D–F) Overall survival plot of ICI treated patients stratified by MUC16 mutational status in male, female, and overall patients. (G–I) Progression-free survival plot of ICI treated patients stratified by MUC16 mutational status in male, female, and overall patients.